

Applicants: D. E. Yelton and M. J. Rosok
Serial No.: 08/905,293
Filed: August 1, 1997
Page 2

In response to the Notice to File Missing Parts of Application issued in connection with the above-identified application on November 18, 1997, a copy of which is enclosed, applicants submit a Declaration and Power of Attorney pursuant to 37 C.F.R. §1.53(d) and in compliance with 37 C.F.R. §1.63. The required fee for this submission is ONE HUNDRED AND THIRTY DOLLARS (\$130.00) and a check including this amount is enclosed.

Please amend the subject application as follows:

In the Specification

At page 2, line 28, please delete "Occasionally, the" and replace it with --The--.

At page 3, line 1, please delete "bond" and replace it with --bond(s)--.

At page 3, line 5, after "fixation" please delete ",".

At page 5, line 4, please delete "cBR96-2" and replace it with -- cBR96-A--.

At page 5, lines 14 and 17, please delete "PCT" and replace it with -- EP--.

At page 5, line 27, please delete "BR96-A-Dox" and replace it with -- cBR96-A-Dox--.

At page 6, line 7, please delete "pNg1/14" and replace it with -- pNg1.14--.

At page 6, line 15, after "deletion" please add --(SEQ ID NO. 10)--.

At page 6, line 24, after "pD17-hJm14.H1" please add --(SEQ ID NO. 22)--.

At page 6, line 26, after "pD17-hG1b" please add --(SEQ ID NO. 23)--.

At page 8, line 20, after the first "region" please add --(SEQ ID NO. 24)--, and after "constant region" please add --(SEQ ID NO. 25)--.

At page 8, line 23, after "constant region" please insert --without the CH₂ domain--.

At page 8, line 23, after the first "region" please add --(SEQ ID NO. 24)--, and after "constant region" please add --(SEQ ID NO. 26)--.

Applicants: D. E. Yelton and M. J. Rosok
Serial No.: 08/905,293
Filed: August 1, 1997
Page 3

At page 8, line 26, after "domain" please add --(SEQ ID NO. 27)--.

At page 9, line 8, please delete "receptor" and replace it with -- portion--.

At page 9, line 10, please delete "the" and replace it with -- normal--, and please delete "of normal".

At page 10, line 19, please delete "encompasses" and replace it with -- encompass--.

At page 12, lines 9, 10 and 11, please delete "PCT" and replace it with -- EP--.

At page 16, line 20, please delete "disease" and replace it with -- antigen-- and please delete "antigen sought to be bound" and replace it with --disease--.

At page 21, line 21, please delete "hBR96-A" and replace it with --hBR96-2A--.

At page 21, line 22, please delete "hBR96" and replace it with --hBR96-2--.

At page 21, line 23, please delete "PCT" and replace it with -- EP--.

At page 27, line 4, please delete "PCT" and replace it with -- EP--.

At page 28, line 28, please delete "and" and replace it with -- ,-- and after "hBR96-2D" please insert --, hBR96-2F, and hBR96-2H--.

At page 29, line 8, please delete "hBR96-2B, -C, -D, -E, -G and -H" and replace it with -- hBR96-C, -E and -G--.

At page 29, line 24, please delete "primary" and replace it with -- plate coat--.

At page 30, line 1, please delete "primary" and replace it with -- plate coat--.

At page 30, line 16, please delete "For conjugation add" and replace it with -- Add--.

At page 30, line 21, after "H₂SO₄" please insert -- ,--.

At page 31, line 1, please delete "BR96-2" and replace it with -- BR96-2--.

At page 31, line 5, please delete "sides" and replace it with -- 3' and 5' ends-- and please delete "E.co47-III" and replace it with --Eco47-III--.

At page 31, line 15, after "3'") please add --, (SEQ ID NO. 1),--.

At page 31, line 16, please delete "GAG" and replace it with -- GGA--.

At page 31, line 17, after "3'") please add --, (SEQ ID NO. 2),--.

At page 31, line 25, after "3'") please add --, (SEQ ID NO. 3),--.

At page 31, line 26, after "3'") please add --, (SEQ ID NO. 4),--.

At page 31, line 26, please delete "GTT" and replace it with -- GGT--.

At page 32, line 26, after "3'") please add --, (SEQ ID NO. 5),--.

At page 32, line 28, after "3'") please add --, (SEQ ID NO. 6),--.

At page 33, line 3, please delete "CH2" and replace it with -- CH1--.

At page 33, line 15, please delete "For digestion" and replace it with -- Digestion--, after "of" please insert --the--, after "IgG1" please insert --vector--, and after "Eco47-III," please insert -- generates--.

At page 33, lines 16-17, please delete "was identified on the constant region sequence of BR96 IgG1 vector".

At page 33, line 27, please delete "a CH2 deleted L6 IgG1 (pNy1.14)" and replace it with --the pNy1.14 vector--.

At page 34, line 1, after "3'") please add --, (SEQ ID NO. 7),--.

At page 34, line 4, after "3'") please add --, (SEQ ID NO. 8),--.

At page 34, line 13, please delete "E. coli DH5a" and replace it with --E. coli DH5α--.

At page 35, line 13, please delete "5" and replace it with --1--.

At page 36, line 1, please delete "toxicity, evaluation" and replace it with -- toxicity. Evaluation--.

At page 36, lines 20-21, please delete "of cBR96-2" and replace it with --cBR96-A--.

At page 36, line 23, please delete "CBR96-2" and replace it with --CBR96-A--.

At page 36, line 28, please delete "e.g." and replace it with --i.e.--.

At page 37, line 13-14, please delete "This finding has motivated our attempts at high levels, and improves the affinity and specificity of BR96 for tumor antigen."

At page 38, line 3, please delete "The polymerase chain reaction(" and ")".

At page 38, lines 6-7, please delete "can be modified in vitro has produced an assortment of novel antibodies".

At page 38, line 20, please delete "As part of a more comprehensive study, we desired to introduce" and replace it with --We introduced--.

At page 39, line 1, please delete "five" and replace it with --Five--.

At page 39, line 2, please delete "clusters-one cluster consisting" and replace it with --cluster. One cluster consisted--.

At page 39, line 3, please delete ";" and replace it with --,-- and delete "consisting" and replace it with --consisted--.

At page 39, line 5, please delete "were interested in constructing" and replace it with --constructed--.

At page 42, line 3, please delete "kpb" and replace it with --kb--.

At page 42, at lines 13, 18 and 23, please delete "Le^y" and replace it with --Le^y--.

At page 42, line 26, please delete "could affect" and replace it with --affected--.

At page 44, line 5, please delete "CH₂" and replace it with --CH₂--.

At page 45, line 27, please delete "mg" and replace it with --ng--.

At page 46, lines 28-29, please delete "Mutant 2H (hBR96 -2H) was also prepared by a combination of these methods".

At page 47, line 20, after "CAGA" please add --, (SEQ ID NO. 7).--.

At page 47, line 22, after "TGC TT" please add --, (SEQ ID NO. 8).--.

At page 47, line 27, after "TGA GG" please add --, (SEQ ID NO. 14).--.

At page 47, line 29, after "TCT TC" please add --, (SEQ ID NO. 15).--.

At page 48, line 3, after "TCA GCC" please add --, (SEQ ID NO. 16).--.

At page 48, line 6, after "GAG GCC" please add --, (SEQ ID NO. 17).--.

At page 48, line 7, after "ACC ATC" please add --, (SEQ ID NO. 18).--.

At page 48, line 9, after "TTT G" please add --, (SEQ ID NO. 19).--.

Applicants: D. E. Yelton and M. J. Rosok
Serial No.: 08/905,293
Filed: August 1, 1997
Page 6

At page 48, line 15, after "CTG GTG" please add --, (SEQ ID NO. 20).--.

At page 48, line 19, after "ACC ATC" please add --, (SEQ ID NO. 21).--.

At page 48, line 25, please delete "refer to previous patent" and please delete "have the least ability to" and replace it with --are cytotoxic--.

At page 48, line 26, please delete "kill cells" and please delete "is" and replace it with --are--.

At page 48, line 27-28, please delete "(least cytotoxic antibodies in the panel)" and replace it with --,--.

At page 48, line 28, before "ADCC", please insert --Loss of--.

At page 48, line 29, please delete "CH2" and replace it with --CH₂--.

At page 49, line 1, please delete "activity" and replace it with --ability--.

In the Sequence Listing:

Please substitute the amended sequence listing (attached herewith as Exhibit 1) for the sequence listing from pages 50-66 of the specification as originally filed.

In addition, applicants provide herewith a computer readable form (CRF) of the sequence listing. Applicants state that the content of the paper and computer readable copies of the sequence listing are the same and include no new matter.

REMARKS

The replacement sequence listing includes sequences from the specification and drawings that were not included in the original sequence listing. In addition, typographical errors appearing in